COMMUNIQUÉS West-GlobeNewswire

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
11/03/2026
Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO [...]
24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making
11/03/2026
DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- 247marketnews.com -- In technology and biotechnology, “unicorn” status is typically reserved for private companies valued at $1 billion or more; often backed by major venture [...]
AiM Medical Robotics adds surgical robotics pioneer, Dr. Yulun Wang, to its world-class Board
11/03/2026
— Renowned founder and robotics visionary joins AiM at a pivotal growth inflection point — WORCESTER, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- AiM Medical Robotics Inc. (AiM), a company developing next-generation MRI- [...]
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, [...]
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
11/03/2026
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis treatment [...]
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea
11/03/2026
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea GMRx2 is an innovative single pill combination of three medicines designed to deliver the blood pressure- [...]
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
11/03/2026
Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “ [...]
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone [...]
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026
Company Also Announces New Name: Quantum Cyber and Change in Nasdaq Ticker symbol BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ) , a molecular genetics diagnostic company [...]
Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
11/03/2026
2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year ; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 [...]
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- [...]
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
11/03/2026
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson’s disease First person has been dosed [...]
Beyond Air to Participate in the 38th Annual Roth Conference in March
11/03/2026
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Annual General Meeting 2026 – GN Store Nord A/S
11/03/2026
Today, GN Store Nord A/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 16, 2026, as set out below. The report by the Board of Directors was [...]
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy Salanersen is a [...]
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
11/03/2026
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas [...]
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11/03/2026
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from [...]
La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2
11/03/2026
Le traitement par niraparib et acétate d’abiratérone démontre un retard cliniquement significatif dans la progression de la maladie, réduisant de près de moitié le risque de progression ou de décès, avec une tendance [...]
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026
Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage Full Year 2025 Revenue [...]

Pages